Recent advances and FDA approvals in nanoformulations for drug delivery

1. Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z (2022) Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B 12:3028–304810.1016/j.apsb.2022.02.025 ↗

2. Gadekar V, Borade Y, KaannauII S, Rajpoot K, Anup N, Tambe V, Kalia K, Tekade RK (2021) Nanomedicines accessible in the market for clinical interventions. J Control Release 10:372–39710.1016/j.jconrel.2020.12.034 ↗

3. Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Aslund AKO, Pottier A, Schifellers R, Ceccaldi A, Schmid R (2020) Delivering the power of nanomedicine to patients today. J Control Release 10:164–17110.1016/j.jconrel.2020.07.007 ↗

4. Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC (2014) State-of-the-art in design rules for drug delivery platforms: lessons from FDA-approved nanomedicines. J Control Release 187:133–14410.1016/j.jconrel.2014.05.036 ↗

5. Rose PG (2005) Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10:205–21410.1634/theoncologist.10-3-205 ↗

6. Halwani AA (2022) Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics 14:10610.3390/pharmaceutics14010106 ↗

7. Anselmo AC, Mitagotri S (2019) Nanoparticles in the clinic: an update. Bioeng Transl Med 4:e1014310.1002/btm2.10143 ↗

8. Shim G, Kim MG, Kim D, Park JY, Oh YK (2017) Nanoformulation-based sequential combination cancer therapy. Adv Drug Deliv Rev 115:57–8110.1016/j.addr.2017.04.003 ↗

9. Adams D et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11–2110.1056/NEJMoa1716153 ↗

10. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC (2018) Liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 36(26):2684–269210.1200/JCO.2017.77.6112 ↗

11. Allyn NM, Luo RH, Hellwarth EB, Swindle-Reilly KE (2022) Considerations for polymers used in ocular drug delivery. Front Med 8:78764410.3389/fmed.2021.787644 ↗

12. Lungwitz U, Breunig M, Blunk T, Göpferich A (2004) Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60(2):247–26610.1016/j.ejpb.2004.11.011 ↗

13. Borchard G (2001) Chitosans for gene delivery. Adv Drug Deliv Rev 52(2):145–5010.1016/S0169-409X(01)00198-3 ↗

14. Dabbaghi A, Ramazani A, Farshchi N, Rezaei A, Bodaghi A, Rezayati S (2021) Synthesis, physical and mechanical properties of amphiphilic hydrogels based on polycaprolactone and polyethylene glycol for bioapplications. J Ind Eng Chem 101:307–32310.1016/j.jiec.2021.05.051 ↗

15. Ramachandran S, Satapathy SR, Dutta T (2022) Delivery strategies for mRNA vaccines. Pharm Med 36:11–2010.1007/s40290-021-00417-5 ↗

16. Guerrini G, Magrì D, Gioria S et al (2022) Characterization of nanoparticles-based vaccines for COVID-19. Nat Nanotechnol 17:570–57610.1038/s41565-022-01129-w ↗

17. Hou X, Zaks T, Langer R, Dong Y (2021) Lipid nanoparticles for mRNA delivery. Nat Rev Mater:1078–1094. https://doi.org/10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗

18. Otsuka H, Nagasaki Y, Kataoka K (2023) PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv 55:403–41910.1016/S0169-409X(02)00226-0 ↗

19. Sadzuka Y, Hirotsu S, Hirota S (1998) Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 127:99–10610.1016/S0304-3835(98)00031-7 ↗

20. Cabral H (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 12:815–82310.1038/nnano.2011.166 ↗

21. Yuan F (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 17:3752–3756